A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: A randomized open-label clinical trial

Background. There are various treatment options available for rosacea, depending on the subtype, but treatment is still generally unsatisfactory. Some reports have indicated beneficial effects of topical pimecrolimus. Aim. To compare the efficacy and safety of pimecrolimus 1% cream and metronidazole 1% cream in the treatment of patients with papulopustular rosacea (PR). Methods. A group of 49 patients with PR was investigated in this single-centre, randomized, open-label study. Patients were randomly assigned treatment with either pimecrolimus 1% cream or metronidazole 1% cream for 12 weeks. Response was evaluated by the inflammatory lesion count, the severity of facial erythema and telangiectasia, Physician's Global Assessment (PGA), and safety and tolerability at baseline and at weeks 3, 6, 9 and 12. Results. In total, 48 patients completed the study. Both treatments were very effective in the treatment of PR. There were no significant differences between the treatments in inflammatory lesion counts, overall erythema severity scores and PGA evaluated from baseline to week 12 (P > 0.05). Neither treatment produced any clinically relevant improvement in telangiectasia. Conclusion. Pimecrolimus cream is no more efficacious than metronidazole cream in the treatment of PR. © 2009 British Association of Dermatologists.

Yazar Koca R.
Altinyazar H.C.
Ankarali H.
Muhtar Ş.
Tekin N.S.
Çinar S.
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/3903
Tek Biçim Adres 10.1111/j.1365-2230.2009.03427.x
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu
Dergi Adı Clinical and Experimental Dermatology
Dergi Cilt Bilgisi 35
Dergi Sayısı 3
Sayfalar 251 - 256
Yayın Yılı 2010
Eser Adı
[dc.title]
A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: A randomized open-label clinical trial
Yazar
[dc.contributor.author]
Koca R.
Yazar
[dc.contributor.author]
Altinyazar H.C.
Yazar
[dc.contributor.author]
Ankarali H.
Yazar
[dc.contributor.author]
Muhtar Ş.
Yazar
[dc.contributor.author]
Tekin N.S.
Yazar
[dc.contributor.author]
Çinar S.
Yayın Yılı
[dc.date.issued]
2010
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Background. There are various treatment options available for rosacea, depending on the subtype, but treatment is still generally unsatisfactory. Some reports have indicated beneficial effects of topical pimecrolimus. Aim. To compare the efficacy and safety of pimecrolimus 1% cream and metronidazole 1% cream in the treatment of patients with papulopustular rosacea (PR). Methods. A group of 49 patients with PR was investigated in this single-centre, randomized, open-label study. Patients were randomly assigned treatment with either pimecrolimus 1% cream or metronidazole 1% cream for 12 weeks. Response was evaluated by the inflammatory lesion count, the severity of facial erythema and telangiectasia, Physician's Global Assessment (PGA), and safety and tolerability at baseline and at weeks 3, 6, 9 and 12. Results. In total, 48 patients completed the study. Both treatments were very effective in the treatment of PR. There were no significant differences between the treatments in inflammatory lesion counts, overall erythema severity scores and PGA evaluated from baseline to week 12 (P > 0.05). Neither treatment produced any clinically relevant improvement in telangiectasia. Conclusion. Pimecrolimus cream is no more efficacious than metronidazole cream in the treatment of PR. © 2009 British Association of Dermatologists.
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
0307-6938
İlk Sayfa Sayısı
[dc.identifier.startpage]
251
Son Sayfa Sayısı
[dc.identifier.endpage]
256
Dergi Adı
[dc.relation.journal]
Clinical and Experimental Dermatology
Dergi Sayısı
[dc.identifier.issue]
3
Dergi Cilt Bilgisi
[dc.identifier.volume]
35
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.1111/j.1365-2230.2009.03427.x
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/3903
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
19
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
13 Şubat 2024 13:46
Google Kontrol
Tıklayınız
treatment patients metronidazole pimecrolimus treatments evaluated inflammatory lesion severity erythema telangiectasia baseline safety rosacea completed efficacious Pimecrolimus Results British Association Dermatologists Neither produced tolerability clinically effective scores overall counts between relevant improvement differences significant Conclusion
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms